Citations

Clear

8 citation(s) found for "Ling, Hua".

Validation of an Epigenetic Prognostic Assay to Accurately Risk-Stratify Patients With Barrett Esophagus
Laun, Sarah , Kann, Lisa , Braun, Jerome J., Gilbert, Stacey, Lunz, Daniel, Pierre, Francia , Kalra, Andrew , Tsai, Hua‐Ling , Wang, Hao , Cheng, Yulan , Ahmed, Yousra , Wang, Kenneth K, Leggett, Cadman L. , Cellini, Ashley, Ioffe, Olga B. , Omstead, Ashten N., Jobe, Blair A. , Korman, Louis Y. , Cornish, Drew, Zellenrath, Pauline A. , Perpetua, Lorrie A., Greenwald, Bruce D. , Maddala, Tara, Meltzer, Stephen J. , Tsai, Hua-Ling , Wang, Hao , Ahmed, Yousra , Leggett, Cadman L , Ioffe, Olga B , Zaidi, Ali Hussainy , Cornish, Drew , Zellenrath, Pauline , Spaander, Manon , Kuipers, Ernst , Greenwald, Bruce D , Meltzer, Stephen J , Braun, Jerome, Ma, Ke , Jit, Simran, Kuipers, Ernst J.

Mayo Clinic

American Journal of Gastroenterology | August 14, 2024 | Volume: 120 | Issue: 6 | Pages: 1296-1306

10.14309/ajg.0000000000003030 | PMID 39140473 Get It

INTRODUCTION: Esophageal adenocarcinoma (EAC) is the second-most lethal cancer in the United States, with Barrett esophagus (BE) being the strongest risk factor. Assessing the future risk of neoplastic progression in patients with BE is difficult; however, high-grade dysplasia (HGD) and early EAC are treatable by endoscopic eradication therapy (EET), with survival rates of 90%. Thus, it would be beneficial to develop a molecular assay to identify high-risk patients, who merit more frequent endoscopic surveillance or EET, as well as low-risk patients, who can avoid EET and undergo less frequent surveillance. METHODS: Deidentified endoscopic biopsies were acquired from 240 patients with BE at 6 centers and confirmed as future progressors or nonprogressors. Tissues were analyzed by a set of methylation-specific biomarker assays. Test performance was assessed in an independent validation set using 4 stratification levels: low risks, low-moderate risks, high-moderate risks, and high risks. RESULTS: Relative to patients in the low-risk group, high-risk patients were 15.2 times more likely to progress within 5 years to HGD or EAC. For patients in the high-risk category, the average risk of progressing to HGD or EAC within 5 years was 21.5%, 4-fold the BE population prevalence within 5 years, whereas low-risk patients had a progression risk of only 1.85%. DISCUSSION: This clinical assay, Esopredict, stratifies future neoplastic progression risk to identify higher-risk patients with BE who can benefit from EET or more frequent surveillance and lower-risk patients who can benefit from reduced surveillance.
Haploidentical Donor Blood or Marrow Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms: Results from a North American Collaboration
Jain, Tania , Tsai, Hua‐Ling , Elmariah, Hany , Vachhani, Pankit , Wall, Sarah , Gondek, Lukasz P. , Bashey, Asad, Keyzner, Alla , Tamari, Roni , Nadiminti, Kalyan , Ali, Haris , Jones, Richard J. , Gondek, Lukasz , Tamari, Roni , Grunwald, Michael , Gerds, Aaron T , McCurdy, Shannon , Al Malki, Monzr M , Ali, Haris , Gupta, Vikas , Jain, Tania , Elmariah, Hany , Karantanos, Theodoros , Grunwald, Michael R. , Abedin, Sameem , Iqbal, Madiha , Gerds, Aaron T. , Viswabandya, Auro , Malki, Monzr M. Al , Varadhan, Ravi , Gupta, Vikas , Otoukesh, Salman

Mayo Clinic

No container title available | March 21, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2691216/v1 | PMID 36993719 Get It

AbstractHaploidentical donors offer a potentially readily available donor, especially for non-White patients, for blood or marrow transplantation (BMT). In this collaboration across North America, we retrospectively analyzed outcomes of first BMT using haploidentical donor and posttransplantation cyclophosphamide (PTCy) in MDS/MPN-overlap neoplasms (MDS/MPN), an otherwise incurable hematological neoplasm. We included 120 patients, 38% of non-White/Caucasian ethnicity, across 15 centers with median age at BMT 62.5 years. The median follow-up is 2.4 years. Graft failure was reported in 6% patients. At 3-years, nonrelapse mortality (NRM) was 25%, relapse 27%, grade 3-4 acute graft versus host disease (GVHD) 12%, chronic GVHD requiring systemic immunosuppression 14%, progression-free survival (PFS) 48% and overall survival (OS) 56%. On multivariable analysis, statistically significant associations included older age at BMT (per decade increment) with NRM (sdHR 3.28, 95%CI 1.30-8.25), PFS (HR 1.98, 95% 1.13-3.45) and OS (HR 2.01, 95% CI 1.11-3.63), presence of mutation in EZH2/RUNX1/SETBP1 with relapse (sdHR 2.61, 95%CI 1.06-6.44), and splenomegaly at BMT/prior splenectomy with OS (HR 2.20, 95%CI 1.04-4.65). Haploidentical donors are a viable option for BMT in MDS/MPN, especially for those disproportionately represented in the unrelated donor registry. Disease-related factors including splenomegaly and high-risk mutations dominate outcomes following BMT.
Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers
Jain, Tania , Tsai, Hua‐Ling , Elmariah, Hany , Vachhani, Pankit , Wall, Sarah , Gondek, Lukasz P. , Bashey, Asad, Keyzner, Alla , Abedin, Sameem , Nadiminti, Kalyan VG, Malki, MHD Monzr M. Al, Ali, Haris , Jones, Richard J., Elmariah, Hany , Gondek, Lukasz , Abedin, Sameem , Karantanos, Theodoros , Grunwald, Michael R. , Iqbal, Madiha , Gerds, Aaron T. , Viswabandya, Auro , McCurdy, Shannon , Varadhan, Ravi , Gupta, Vikas , Otoukesh, Salman

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7731-7733

10.1182/blood-2022-157985 Get It

The diagnostic utility of targeted gene panel sequencing in discriminating etiologies of cytopenia
Zheng, Gang , Chen, Ping , Pallavajjalla, Aparna, Haley, Lisa , Gondek, Lukasz P. , Ling, Hua , Marchi, Federico De , Lin, Ming‐Tseh, Gocke, Christopher D. , De Marchi, Federico , Gondek, Lukasz , Dezern, Amy Elizabeth

Mayo Clinic

American Journal of Hematology | July 27, 2019 | Volume: 94 | Issue: 10 | Pages: 1141-1148

10.1002/ajh.25592 | PMID 31350794 Get It

Abstract The diagnostic utility of somatic mutations in the context of cytopenias is unclear: clonal hematopoiesis can be found in healthy individuals, patients with aplastic anemia (AA), clonal cytopenia of undetermined significance (CCUS) and myelodysplastic syndrome (MDS). We examined a cohort of 207 well‐characterized cytopenic patients with a 640‐gene next generation sequencing (NGS) panel and compared its diagnostic utility with a “virtual” 41 gene panel. The TET2 , SF3B1 , ASXL1 , and TP53 were the most commonly mutated genes (frequency > 10%). Mutations in the 640‐gene panel show high sensitivity (98.3%) but low specificity (47.6%) for diagnosis of MDS. Notably, mutations of splicing factors and genes in the RAS pathway are relatively specific to MDS. Furthermore, high variant allele frequency (VAF) predicts MDS: when the VAF is set at 20%, the positive predictive value (PPV) for MDS is 95.9%, with a specificity of 95.3%. The presence of two or more somatic mutations with ≥10% VAF showed a PPV of 95.2%. While the “virtual” 41‐gene panel showed a mild decrease in sensitivity (95.7% vs 98.3%), 100% specificity was observed when either VAF was set at ≥20% (100% vs 95.3%), or two or more somatic mutations had VAFs ≥ 10%. Our study shows targeted gene panel sequencing improves the diagnostic approach and accuracy for unexplained cytopenia, with its high sensitivity and high PPV for MDS when applying VAF cutoffs. Furthermore, a 41‐gene panel was shown to have at least comparable performance characteristics to the large 640‐gene panel.
The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers
Wang, Zhaoming , Schumacher, Fredrick R. , Gayther, Simon A. , Casey, Graham , Sellers, Thomas A. , Gruber, Stephen B., Dunning, Alison M. , Michailidou, Kyriaki , Fachal, Laura , Doheny, Kimberly F. , Li, Yafang , Xiao, Xiangjun , Romm, Jane, Pugh, Elizabeth, Coetzee, Gerhard A. , Hazelett, Dennis J. , Bojesen, Stig E. , Caga-Anan, Charlisse , Haiman, Christopher A. , Kamal, Ahsan , Luccarini, Craig , Tessier, Daniel C., Vincent, Daniel , Bacot, François, Berg, David Van Den , Nelson, Stefanie A. , Demetriades, Stephen, Goldgar, David E., Forman, Judith L., Conti, David V. , Bickeböller, Heike , Risch, Angela , Waldenberger, Mélanie , Brüske‐Hohlfeld, Irene, Hicks, Belynda , McGuffog, Lesley, Kuchenbaecker, Karoline , Soucy, Penny, Manz, Judith, Cunningham, Julie M. , Butterbach, Katja, Kote‐Jarai, Zsofia , Kraft, Peter , Lindström, Sara , Adams, Marcia, McKay, James , Phelan, Catherine M., Benlloch, Sara, Kelemen, Linda E., Brennan, Paul , Riggan, Marjorie J. , O’Mara, Tracy A. , Shen, Hongbing , Shi, Yongyong , Thompson, Deborah J. , Goodman, Marc T. , Nielsen, Sune F. , LaBoissière, Sylvie, Schmit, Stephanie L. , Shelford, Tameka, Edlund, Christopher K., Taylor, Jack A. , Field, John K. , Park, Sue K. , Offit, Kenneth , Thomassen, Mads , Schmutzler, Rita K., Ottini, Laura , Hung, Rayjean J., Olama, Ali Amin Al , Peters, Ulrike , Eeles, Rosalind A. , Seldin, Michael F., Gillanders, Elizabeth M. , Seminara, Daniela, Antoniou, Antonis C. , Chenevix‐Trench, Georgia , Simard, Jacques , Easton, Douglas F. , Durocher, Francine , Hung, Rayjean J. , Amos, Christopher I. , Dennis, Joe , Byun, Jinyoung , Hunter, David J. , Spurdle, Amanda B. , Couch, Fergus J. , Giles, Graham G. , Ling, Hua , Lee, Andrew , FitzGerald, Liesel M. , Berchuck, Andrew , Marchini, Jonathan , Pharoah, Paul D.P. , Chanock, Stephen Jacob , Hazelett, Dennis J , Eeles, Rosalind A , Van Den Berg, David J , Hung, Rayjean J , Wang, Zhaoming , O'Mara, Tracy A , Field, John K , Dunning, Alison M , Michailidou, Kyriaki , Taylor, Jack A , Kraft, Peter , Simard, Jacques , Chenevix-Trench, Georgia , Ottini, Laura , Conti, David V , Bojesen, Stig E , Risch, Angela , Bickeböller, Heike , Shen, Hongbing , Goodman, Marc T , Fachal, Laura

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | October 3, 2016 | Volume: 26 | Issue: 1 | Pages: 126-135

10.1158/1055-9965.epi-16-0106 | PMID 27697780 Get It

Abstract Background: Common cancers develop through a multistep process often including inherited susceptibility. Collaboration among multiple institutions, and funding from multiple sources, has allowed the development of an inexpensive genotyping microarray, the OncoArray. The array includes a genome-wide backbone, comprising 230,000 SNPs tagging most common genetic variants, together with dense mapping of known susceptibility regions, rare variants from sequencing experiments, pharmacogenetic markers, and cancer-related traits. Methods: The OncoArray can be genotyped using a novel technology developed by Illumina to facilitate efficient genotyping. The consortium developed standard approaches for selecting SNPs for study, for quality control of markers, and for ancestry analysis. The array was genotyped at selected sites and with prespecified replicate samples to permit evaluation of genotyping accuracy among centers and by ethnic background. Results: The OncoArray consortium genotyped 447,705 samples. A total of 494,763 SNPs passed quality control steps with a sample success rate of 97% of the samples. Participating sites performed ancestry analysis using a common set of markers and a scoring algorithm based on principal components analysis. Conclusions: Results from these analyses will enable researchers to identify new susceptibility loci, perform fine-mapping of new or known loci associated with either single or multiple cancers, assess the degree of overlap in cancer causation and pleiotropic effects of loci that have been identified for disease-specific risk, and jointly model genetic, environmental, and lifestyle-related exposures. Impact: Ongoing analyses will shed light on etiology and risk assessment for many types of cancer. Cancer Epidemiol Biomarkers Prev; 26(1); 126–35. ©2016 AACR.
A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia
Pratz, Keith W. , Gojo, Ivana , Litzow, Mark R. , McDevitt, Michael A. , Ji, Jiuping , Karnitz, Larry M., Herman, James G. , Kinders, Robert J. , Gore, Steven D. , Showel, Margaret M. , Gladstone, Douglas E. , Tsai, Hua-Ling, Rosner, Gary L. , Chen, Alice P. , Karp, Judith E. , Kaufmann, Scott H. , Rudek, Michelle A. , Smith, B. Douglas , Carraway, Hetty E. , Levis, Mark J. , Tsai, Hua‐Ling

Mayo Clinic

Clinical Cancer Research | August 22, 2016 | Volume: 23 | Issue: 4 | Pages: 899-907

10.1158/1078-0432.ccr-16-1274 | PMID 27551000 Get It

Abstract Purpose: The PARP inhibitor veliparib delays DNA repair and potentiates cytotoxicity of multiple classes of chemotherapy drugs, including topoisomerase I inhibitors and platinating agents. This study evaluated veliparib incorporation into leukemia induction therapy using a previously described topotecan/carboplatin backbone. Experimental Design: Employing a 3+3 trial design, we administered escalating doses of veliparib combined with topotecan + carboplatin in relapsed or refractory acute leukemias, aggressive myeloproliferative neoplasms (MPN), and chronic myelomonocytic leukemia (CMML). Results: A total of 99 patients received veliparib 10–100 mg orally twice daily on days 1–8, 1–14, or 1–21 along with continuous infusion topotecan 1.0–1.2 mg/m2/d + carboplatin 120–150 mg/m2/d on days 3–7. The MTD was veliparib 80 mg twice daily for up to 21 days with topotecan 1.2 mg/m2/d + carboplatin 150 mg/m2/d. Mucositis was dose limiting and correlated with high veliparib concentrations. The response rate was 33% overall (33/99: 14 CR, 11 CRi, 8 PR) but was 64% (14/22) for patients with antecedent or associated aggressive MPNs or CMML. Leukemias with baseline DNA repair defects, as evidenced by impaired DNA damage–induced FANCD2 monoubiquitination, had improved survival [HR = 0.56 (95% confidence interval, 0.27–0.92)]. A single 80-mg dose of veliparib, as well as veliparib in combination with topotecan + carboplatin, induced DNA damage as manifested by histone H2AX phosphorylation in CD34+ leukemia cells, with greater phosphorylation in cells from responders. Conclusions: The veliparib/topotecan/carboplatin combination warrants further investigation, particularly in patients with aggressive MPNs, CMML, and MPN- or CMML-related acute leukemias. Clin Cancer Res; 23(4); 899–907. ©2016 AACR.
Genome-Wide Association Analysis of Ischemic Stroke in Young Adults
Cheng, Yu-Ching , O’Connell, Jeffrey R. , Dueker, Nicole , McArdle, Patrick F. , Sparks, Mary J., Shen, Jess, Laurie, Cathy C. , Doheny, Kimberly F. , Pugh, Elizabeth, Brott, Thomas G. , Brown, Robert D., Nalls, Michael A., Rich, Stephen S. , Worrall, Bradford B. , Anderson, Christopher D. , Biffi, Alessandro , Cortellini, Lynelle, Furie, Karen L., Rost, Natalia S. , Manolio, Teri A. , Kittner, Steven J. , Mitchell, Braxton D. , Cole, John W. , Stine, Oscar Colin , Nelson, Sarah C. , Ling, Hua , Meschia, James F. , Rosand, Jonathan M. , Rich, Stephen S , Mitchell, Braxton D

Mayo Clinic

G3 Genes|Genomes|Genetics | December 14, 2011 | Volume: 1 | Issue: 6 | Pages: 505-514

10.1534/g3.111.001164 | PMID 22384361 Get It

Abstract Ischemic stroke (IS) is among the leading causes of death in Western countries. There is a significant genetic component to IS susceptibility, especially among young adults. To date, research to identify genetic loci predisposing to stroke has met only with limited success. We performed a genome-wide association (GWA) analysis of early-onset IS to identify potential stroke susceptibility loci. The GWA analysis was conducted by genotyping 1 million SNPs in a biracial population of 889 IS cases and 927 controls, ages 15–49 years. Genotypes were imputed using the HapMap3 reference panel to provide 1.4 million SNPs for analysis. Logistic regression models adjusting for age, recruitment stages, and population structure were used to determine the association of IS with individual SNPs. Although no single SNP reached genome-wide significance (P < 5 × 10−8), we identified two SNPs in chromosome 2q23.3, rs2304556 (in FMNL2; P = 1.2 × 10−7) and rs1986743 (in ARL6IP6; P = 2.7 × 10−7), strongly associated with early-onset stroke. These data suggest that a novel locus on human chromosome 2q23.3 may be associated with IS susceptibility among young adults.
Quality Control Procedures for Genome‐Wide Association Studies
Turner, Stephen , Armstrong, Loren L., Bradford, Yuki, Carlson, Christopher S. , Crawford, Dana C. , Crenshaw, Andrew, Doheny, Kimberly F. , Haines, Jonathan L. , Hayes, Geoffrey, Jarvik, Gail P. , Jiang, Lan , Li, Rongling, Manolio, Teri A. , Matsumoto, Martha, McCarty, Catherine A. , McDavid, Andrew , Mirel, Daniel B., Paschall, Justin, Pugh, Elizabeth, Rasmussen, Luke V. , Wilke, Russell A. , Zuvich, Rebecca L., Ritchie, Marylyn D. , Andrade, Mariza de , Kullo, Iftikhar J. , Ling, Hua , Jarvik, Gail P , Rasmussen, Luke V

Mayo Clinic

Current Protocols in Human Genetics | January 13, 2011 | Volume: 68 | Issue: 1 | Pages: No page available

10.1002/0471142905.hg0119s68 | PMID 21234875 Get It

AbstractGenome‐wide association studies (GWAS) are being conducted at an unprecedented rate in population‐based cohorts and have increased our understanding of the pathophysiology of complex disease. Regardless of context, the practical utility of this information will ultimately depend upon the quality of the original data. Quality control (QC) procedures for GWAS are computationally intensive, operationally challenging, and constantly evolving. Here we enumerate some of the challenges in QC of GWAS data and describe the approaches that the electronic MEdical Records and Genomics (eMERGE) network is using for quality assurance in GWAS data, thereby minimizing potential bias and error in GWAS results. We discuss common issues associated with QC of GWAS data, including data file formats, software packages for data manipulation and analysis, sex chromosome anomalies, sample identity, sample relatedness, population substructure, batch effects, and marker quality. We propose best practices and discuss areas of ongoing and future research. Curr. Protoc. Hum. Genet. 68:1.19.1‐1.19.18 © 2011 by John Wiley & Sons, Inc.